Tumor Hospital of Gansu Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2019
NCT03955367
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Gansu Wuwei Tumour Hospital | Tumor Hospital of Gansu

Active Ingredients

Drugs in Phase 4 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Drugs in Phase 3 Trials (2)

docetaxel (taxotere) (1 trial)

nedaplatin (1 trial)

Drugs in Phase 2 Trials (2)

cyclosporine (sandimmune) (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5